【摘要】 目的 观察化疗联合小剂量白介素-2(IL-2)治疗初发急性髓系白血病(AML)的近期疗效及安全性。方法 将58例AML患者随机分为观察组(29例)和对照组(29例)。对照组单纯采用化疗,观察组在化疗基础上加用IL-2 100万IU/d,14d为1个疗程,2个疗程后评价疗效及不良反应。结果 患者对IL-2耐受性良好,观察组完全缓解(CR)率、达CR所需时间与对照组比较差异无统计学意义[62.1%vs 58.6%,(18.5±5.2)d vs(19.2±4.3)d,P>0.05];观察组Ⅲ、Ⅳ级血液学毒性及感染的发生率均显著低于对照组,差异有统计学意义(P<0.05)。结论 化疗联合小剂量IL-2治疗初治急性髓系白血病不能提高CR,但IL-2可降低感染风险,减轻血液学毒性。更多还原

【Abstract】 Objective To observe the efficacy and safety of chemotherapy in combination with low-dose interleukin-2 in the treatment of newly diagnosed acute myeloid leukemia,AML.Methods Fifty-eight patients with AML were randomly divided into observation group and control group.The control group was treated only with chemotherapy,the observation group was given chemotherapy based on injection of interleukin-2 1,000,OOOIU,14 days for a course of treatment,evaluated the efficacy and adverse reactions after 2 cycles.Results IL-2 was well tolerated by the patients.The difference between the two groups in complete remission(CR) rate(62.1%vs 58.6%) and the time acquire to CR[(18.5 ± 5.2)d vs(19.2±4.3) d,P>0.05]was not significant;the incidences of hematological toxicities of grade Ⅲ and grade Ⅳ,and infections were significantly lower in the observation group.The difference was statistically significant(P<0.05).Conclusion Chemotherapy in combination with low-dose interleukin-2 can not increase CR rate in the treatment of AML,but IL-2 can reduce the risk of infection,reducing the hematologic toxicities.更多还原